Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9737042 | 1.00 | MPI (0.40) | MPIAKR1B1PTPN1 | |
| SCHEMBL9738005 | 1.00 | MPI (0.40) | MPIAKR1B1PTPN1 | |
| SCHEMBL9737690 | 1.00 | MPI (0.40) | MPIAKR1B1PTPN1 | |
| SCHEMBL9736332 | 1.00 | MPI (0.40) | MPIAKR1B1PTPN1 | |
| SCHEMBL9737340 | 1.00 | MPI (0.40) | MPIAKR1B1PTPN1 | |
| SCHEMBL9737878 | 0.96 | MPI (0.38) | MPIAKR1B1PTPN1 | |
| SCHEMBL3080845 | 0.96 | MPI (0.38) | MPIAKR1B1PTPN1 | |
| SCHEMBL3069342 | 0.96 | MPI (0.38) | MPIAKR1B1PTPN1 | |
| SCHEMBL18486483 | 0.96 | MPI (0.38) | MPIAKR1B1PTPN1 | |
| SCHEMBL3069000 | 0.96 | MPI (0.38) | MPIAKR1B1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0506772-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A PHOSPHOSUGAR | PERSTORP AB (SE) | 1992-10-07 | — | — | EP | claimed |
| WO-1991009604-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A PHOSPHOSUGAR | PERSTORP AB (SE) | 1991-07-11 | — | — | WO | claimed |
| US-20250347698-A1 | Multi-Omics Biomarker Detection System and Methods for Disease Diagnostics | COMPLETE OMICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12370209-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4463232-A1 | SOLID STATE FORMS OF RUCAPARIB TOSYLATE | Assia Chemical Industries Ltd. (IL) | 2024-11-20 | — | — | EP | disclosed |
| US-12083114-B2 | Inhibitors of SARM1 in combination with neuro-protective agents | DISARM THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240230622-A9 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240180892-A1 | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132) | IMMUNOMEDICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240133865-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240091249-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11857561-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20070078100-A1 | Methods of detecting poly(adp-ribose) polymerase and other nad+ utilizing enzymes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2005038043-A2 | METHODS OF DETECTING POLY (ADP-RIBOSE) POLYMERASE AND OTHER NAD+UTILIZING ENZYMES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1458688-A1 | QUINAZOLINONE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6506572-B2 | Inhibitor of niacinamide phosphoribosyl transferase (NAPRT) | KLINGE PHARMA GMBH (DE) | 2003-01-14 | — | — | US | disclosed |
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | KLINGE PHARMA GMBH | 2002-10-31 | — | — | US | disclosed |
| CN-1345733-A | Novel polypeptide-protein 11.55 containing polyadenylic diphosphoribose and polynucleotide for encoding said polypeptide | SHANGHAI BIOWINDOW GENE DEV (CN) | 2002-04-24 | — | — | CN | disclosed |
| EP-1031564-A1 | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy | Klinge Pharma GmbH (DE) | 2000-08-30 | — | — | EP | disclosed |
| EP-0506772-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A PHOSPHOSUGAR | PERSTORP AB (SE) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991009604-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A PHOSPHOSUGAR | PERSTORP AB (SE) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370209-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | ADAR, CD38, PARP1 | MPI 1767/4885AKR1B1 174/4885PTPN1 4619/4885 |
| US-12083114-B2 | Inhibitors of SARM1 in combination with neuro-protective agents | SARM1, SMN1; SMN2, SARNP | MPI 3498/4885AKR1B1 4448/4885PTPN1 4373/4885 |
| US-11857561-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | ADAR, CD38, PARP1 | MPI 1767/4885AKR1B1 174/4885PTPN1 4619/4885 |
| US-20070078100-A1 | Methods of detecting poly(adp-ribose) polymerase and other nad+ utilizing enzymes | PARP1, PARP11, PARP3 | MPI 361/4885AKR1B1 612/4885PTPN1 4435/4885 |
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | NAMPT, NAPRT, NNT | MPI 363/4885AKR1B1 599/4885PTPN1 3519/4885 |
| US-20240091249-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | ADAR, CD38, PARP1 | MPI 1762/4885AKR1B1 167/4885PTPN1 4648/4885 |
| US-20240180892-A1 | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132) | PARP2, CD22, DOCK2 | MPI 1318/4885AKR1B1 3956/4885PTPN1 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.